Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Receivables (2023 - 2025)

Metagenomi (MGX) has disclosed Receivables for 3 consecutive years, with $305000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Receivables fell 75.74% to $305000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $305000.0, a 75.74% decrease, with the full-year FY2025 number at $305000.0, down 72.27% from a year prior.
  • Receivables was $305000.0 for Q4 2025 at Metagenomi, down from $960000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $2.5 million in Q4 2023 to a low of $305000.0 in Q4 2025.
  • A 3-year average of $1.2 million and a median of $960000.0 in 2025 define the central range for Receivables.
  • Biggest YoY gain for Receivables was 62.99% in 2025; the steepest drop was 75.74% in 2025.
  • Metagenomi's Receivables stood at $2.5 million in 2023, then plummeted by 48.71% to $1.3 million in 2024, then tumbled by 75.74% to $305000.0 in 2025.
  • Per Business Quant, the three most recent readings for MGX's Receivables are $305000.0 (Q4 2025), $960000.0 (Q3 2025), and $900000.0 (Q2 2025).